Company Information

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE937.654.25 (+0.46 %)
PREV CLOSE ( ) 933.40
OPEN PRICE ( ) 937.15
BID PRICE (QTY) 937.05 (18)
OFFER PRICE (QTY) 937.85 (12)
VOLUME 21615
TODAY'S LOW / HIGH ( )925.20 940.00
52 WK LOW / HIGH ( )482.55 1031.3
NSE937.854.35 (+0.47 %)
PREV CLOSE( ) 933.50
OPEN PRICE ( ) 935.15
BID PRICE (QTY) 937.60 (3)
OFFER PRICE (QTY) 937.85 (85)
VOLUME 981313
TODAY'S LOW / HIGH( ) 925.40 941.85
52 WK LOW / HIGH ( )484.95 1031.7
ChairmanPankaj R Patel
Managing DirectorSharvil P Patel
Company SecretaryDhaval N Soni
Executive DirectorGanesh N Nayak
Non Executive DirectorMukesh M Patel
Non Executive Independent DirectorNitin R Desai
Bhadresh K Shah
Dharmishta N Raval
Apurva S Diwanji
Akhil Monappa
Upasana Konidela
Incorporation Year : 15-05 1995

Registered Office :

Address : Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway Ahmedabad,
Gujarat-382481 .

Phone : 079-71800000 / 48040000

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.